Trial · NCT04596995
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 26
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Rozanolixizumab | 3 | 43 | 11 |
| other | Diarrhoea | Gastrointestinal disorders | Rozanolixizumab | 5 | 43 | 5 |
| other | Nausea | Gastrointestinal disorders | Rozanolixizumab | 5 | 43 | 9 |
| other | Vomiting | Gastrointestinal disorders | Rozanolixizumab | 3 | 43 | 7 |
| other | Fatigue | General disorders | Rozanolixizumab | 5 | 43 | 6 |
| other | Pyrexia | General disorders | Rozanolixizumab | 9 | 43 | 26 |
| other | COVID-19 | Infections and infestations | Rozanolixizumab | 7 | 43 | 8 |
| other | Pharyngitis | Infections and infestations | Rozanolixizumab | 4 | 43 | 4 |
| other | Upper respiratory tract infection | Infections and infestations | Rozanolixizumab | 3 | 43 | 4 |
| other | Contusion | Injury, poisoning and procedural complications | Rozanolixizumab | 3 | 43 | 3 |
| other | Body temperature increased | Investigations | Rozanolixizumab | 5 | 43 | 8 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Rozanolixizumab | 3 | 43 | 3 |
| other | Headache | Nervous system disorders | Rozanolixizumab | 18 | 43 | 58 |
| other | Petechiae | Skin and subcutaneous tissue disorders | Rozanolixizumab | 3 | 43 | 3 |
| other | Rash | Skin and subcutaneous tissue disorders | Rozanolixizumab | 3 | 43 | 4 |
| serious | Immune thrombocytopenia | Blood and lymphatic system disorders | Rozanolixizumab | 1 | 43 | 1 |
| serious | Pyrexia | General disorders | Rozanolixizumab | 1 | 43 | 1 |
| serious | COVID-19 | Infections and infestations | Rozanolixizumab | 2 | 43 | 2 |
| serious | Joint dislocation | Injury, poisoning and procedural complications | Rozanolixizumab | 1 | 43 | 1 |
| serious | Radius fracture | Injury, poisoning and procedural complications | Rozanolixizumab | 1 | 43 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04596995/events